Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 2-amino-n-((1s)-1-(8-((1-methyl-1h-pyrazol-4-yl)ethynyl)-1-oxo-2-phenyl-1,2-dihydro-3-isoquinolinyl)ethyl)pyrazolo(1,5-a)pyrimidine-3-carboxamide
2. Ipi-549
1. Ipi-549
2. 1693758-51-8
3. Eganelisib [usan]
4. Pi3k-gamma Inhibitor Ipi-549
5. Fof5155fmz
6. Ipi549
7. Chembl3984425
8. 2-amino-n-[(1s)-1-[8-[2-(1-methylpyrazol-4-yl)ethynyl]-1-oxo-2-phenylisoquinolin-3-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
9. (s)-2-amino-n-(1-(8-((1-methyl-1h-pyrazol-4-yl)ethynyl)-1-oxo-2-phenyl-1,2- Dihydroisoquinolin-3-yl)ethyl)pyrazolo(1,5-a)pyrimidine-3-carboxamide
10. 2-amino-n-[(1s)-1-{8-[(1-methyl-1h-pyrazol-4-yl)ethynyl]-1-oxo-2-phenyl-1,2-dihydroisoquinolin-3-yl}ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
11. Pyrazolo(1,5-a)pyrimidine-3-carboxamide, 2-amino-n-((1s)-1-(1,2-dihydro-8-(2-(1-methyl-1h-pyrazol-4-yl)ethynyl)-1-oxo-2-phenyl-3-isoquinolinyl)ethyl)-
12. Pyrazolo[1,5-a]pyrimidine-3-carboxamide, 2-amino-n-[(1s)-1-[1,2-dihydro-8-[2-(1-methyl-1h-pyrazol-4-yl)ethynyl]-1-oxo-2-phenyl-3-isoquinolinyl]ethyl]-
13. Eganelisib [inn]
14. Unii-fof5155fmz
15. Eganelisib [who-dd]
16. Gtpl9563
17. Schembl16629991
18. Dtxsid301336580
19. Ipi-549(ipi549)
20. Amy16733
21. Ex-a1057
22. V7y
23. Bdbm50192880
24. Mfcd30533720
25. Nsc795067
26. Nsc801002
27. S8330
28. Who 11571
29. Zinc584906867
30. Ccg-269905
31. Cs-6106
32. Nsc-795067
33. Nsc-801002
34. Compound 26 [pmid: 27660692]
35. Ac-29898
36. As-55938
37. Hy-100716
38. A16332
39. 2-amino-n-((1s)-1-(8-((1-methyl-1h-pyrazol-4-yl)ethynyl)-1-oxo-2-phenyl-1,2-dihydro-3-isoquinolinyl)ethyl)pyrazolo(1,5-a)pyrimidine-3-carboxamide
40. 2-amino-n-[(1s)-1-{8-[2-(1-methyl-1h-pyrazol-4-yl)ethynyl]-1-oxo-2-phenyl- 1,2-dihydroisoquinolin-3-yl}ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
| Molecular Weight | 528.6 g/mol |
|---|---|
| Molecular Formula | C30H24N8O2 |
| XLogP3 | 3.2 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 6 |
| Exact Mass | 528.20222204 g/mol |
| Monoisotopic Mass | 528.20222204 g/mol |
| Topological Polar Surface Area | 123 Ų |
| Heavy Atom Count | 40 |
| Formal Charge | 0 |
| Complexity | 1060 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Eganelisib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Eganelisib, including repackagers and relabelers. The FDA regulates Eganelisib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Eganelisib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Eganelisib supplier is an individual or a company that provides Eganelisib active pharmaceutical ingredient (API) or Eganelisib finished formulations upon request. The Eganelisib suppliers may include Eganelisib API manufacturers, exporters, distributors and traders.
Eganelisib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Eganelisib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Eganelisib GMP manufacturer or Eganelisib GMP API supplier for your needs.
A Eganelisib CoA (Certificate of Analysis) is a formal document that attests to Eganelisib's compliance with Eganelisib specifications and serves as a tool for batch-level quality control.
Eganelisib CoA mostly includes findings from lab analyses of a specific batch. For each Eganelisib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Eganelisib may be tested according to a variety of international standards, such as European Pharmacopoeia (Eganelisib EP), Eganelisib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Eganelisib USP).
LOOKING FOR A SUPPLIER?
